Meeting
2024 ASCO Annual Meeting
Outpatient blinatumomab with digital monitoring in patients with measurable residual disease positive (MRD+) B-ALL in a phase 4 study.
Authors
Timothy S. Pardee
Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston Salem, NC
Timothy S. Pardee , Juan Varela , Deepa Jeyakumar , Michael Kenneth Keng , Michal Bar-Natan , Krishna Gundabolu , Arlene Gayle , Christopher McCann , Qing Xia , Sofia Ganzha , Noemi Mergen , Faraz Zaman , Paul R. Gordon , Sharif S. Khan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04506086
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6544)
DOI
10.1200/JCO.2024.42.16_suppl.6544
Abstract #
6544
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
First Author: Sharif S. Khan